U.S. markets open in 6 hours 57 minutes
  • S&P Futures

    4,248.00
    +2.25 (+0.05%)
     
  • Dow Futures

    34,474.00
    +12.00 (+0.03%)
     
  • Nasdaq Futures

    14,012.75
    +18.50 (+0.13%)
     
  • Russell 2000 Futures

    2,331.60
    +1.10 (+0.05%)
     
  • Crude Oil

    71.24
    +0.33 (+0.47%)
     
  • Gold

    1,862.20
    -17.40 (-0.93%)
     
  • Silver

    27.91
    -0.24 (-0.84%)
     
  • EUR/USD

    1.2104
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.4620
    0.0000 (0.00%)
     
  • Vix

    15.65
    -0.45 (-2.80%)
     
  • GBP/USD

    1.4102
    -0.0014 (-0.10%)
     
  • USD/JPY

    109.6780
    +0.0430 (+0.04%)
     
  • BTC-USD

    39,284.41
    +4,151.02 (+11.82%)
     
  • CMC Crypto 200

    979.89
    +38.07 (+4.04%)
     
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting one-on-one meetings at the following investor conferences:

  • H.C. Wainwright 22nd Annual Global Investment Conference
    Presentation Date: Monday, September 14, 2020
    Time: 3:30 p.m. ET

  • 2020 Cantor Global Virtual Healthcare Conference
    Presentation Date: Wednesday, September 16, 2020 (Fireside Chat)
    Time: 2:40 p.m. ET

A live webcast of the presentations will be available on the investor relations page of the company’s corporate website at https://ir.aldeyra.com. After the live webcast, the events will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005197/en/

Contacts

Corporate Contact:
David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcmullin@aldeyra.com

Investor & Media Contact:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
ALDX@investorrelations.com